Liu Liping, Aesif Scott W, Kipp Benjamin R, Voss Jesse S, Daniel Silver, Aubry Marie Christine, Boland Jennifer M
*Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN †Department of Pathology, Northwestern Medicine Central DuPage Hospital, Winfield, IL.
Am J Surg Pathol. 2016 Dec;40(12):1631-1636. doi: 10.1097/PAS.0000000000000707.
Ciliated muconodular papillary tumors (CMPTs) are rare peripheral lung lesions, characterized by papillary architecture and ciliated columnar cells admixed with mucinous cells and basal cells. They often have prominent surrounding intra-alveolar mucin, which can lead to diagnostic confusion with mucinous adenocarcinoma. Recognition of the ciliated component is the key to diagnosis of CMPT. The literature contains few reported cases to date, all occurring in East-Asian patients. Although follow-up data are limited, CMPT seems to be an indolent tumor with very good prognosis, leading some to question whether it is a reactive or hamartomatous lesion. However, a very recent molecular study has identified BRAF (40%) and EGFR (30%) alterations in CMPT, supporting a truly neoplastic process. Here for the first time, we report 4 cases of morphologically typical CMPT in western patients, occurring in 1 man (60 y) and 3 women (71 to 83 y). Interestingly, 1 case occurred in background of pronounced small airway disease with necrotizing bronchiolitis and multiple carcinoid tumorlets. We further analyzed 1 tumor using a 50 gene next-generation sequencing oncology panel that identified 2 pathogenic mutations (BRAF V600E and AKT1 E17K). Our study is the first to describe that CMPT can occur in western (non-Asian) patients. Our data confirm BRAF V600E mutation as a probable driver in a subset of these tumors, along with AKT1 mutation, which further supports that CMPT are indolent pulmonary neoplasms.
纤毛黏液结节状乳头状瘤(CMPTs)是一种罕见的肺外周病变,其特征为乳头状结构以及混有黏液细胞和基底细胞的纤毛柱状细胞。它们通常有显著的肺泡内周围黏液,这可能导致与黏液腺癌的诊断混淆。识别纤毛成分是诊断CMPT的关键。迄今为止,文献报道的病例很少,均发生在东亚患者中。尽管随访数据有限,但CMPT似乎是一种惰性肿瘤,预后非常好,这使得一些人质疑它是否是一种反应性或错构瘤性病变。然而,最近的一项分子研究在CMPT中发现了BRAF(40%)和EGFR(30%)改变,支持了其真正的肿瘤形成过程。在此,我们首次报告4例形态学典型的CMPT发生在西方患者中,其中1例为男性(60岁),3例为女性(71至83岁)。有趣的是,1例发生在有明显小气道疾病伴坏死性细支气管炎和多个类癌小结的背景下。我们进一步使用50基因下一代测序肿瘤学检测板分析了1例肿瘤,发现了2个致病突变(BRAF V600E和AKT1 E17K)。我们的研究首次描述了CMPT可发生在西方(非亚洲)患者中。我们的数据证实BRAF V600E突变可能是这些肿瘤一部分的驱动因素,同时还有AKT1突变,这进一步支持CMPT是惰性肺肿瘤。